Los Angeles, April 19, 2021— Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has approved its TRE-515 investigational new drug (IND) application for the treatment of solid tumor malignancies. Trethera will […]
Los Angeles, March 16, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases announces that Frank Baxter has been appointed as special advisor. He will be advising Trethera and its board of directors on financing options including private equity, public […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2021-03-16 16:50:462021-03-16 16:52:33Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor
Los Angeles, February 24, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce completion of its Seed Preferred 3 Stock financing. Trethera raised an aggregate of $3.2 million from its existing investors, which funds will be […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2021-02-24 03:50:002021-03-08 18:05:11Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors
Los Angeles, January 7, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515, Trethera’s first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM). […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2021-01-07 04:06:002021-03-08 17:55:55Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
Los Angeles, December 8, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce that distinguished researcher Michael Shepard, PhD has joined Trethera’s Scientific Advisory Board. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2020-12-08 04:17:002021-03-08 18:11:32Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board
Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy
/in News /by TretheraLos Angeles, April 19, 2021— Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has approved its TRE-515 investigational new drug (IND) application for the treatment of solid tumor malignancies. Trethera will […]
Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor
/in News /by TretheraLos Angeles, March 16, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases announces that Frank Baxter has been appointed as special advisor. He will be advising Trethera and its board of directors on financing options including private equity, public […]
Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors
/in News /by TretheraLos Angeles, February 24, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce completion of its Seed Preferred 3 Stock financing. Trethera raised an aggregate of $3.2 million from its existing investors, which funds will be […]
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
/in News /by TretheraLos Angeles, January 7, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515, Trethera’s first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM). […]
Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board
/in News /by TretheraLos Angeles, December 8, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce that distinguished researcher Michael Shepard, PhD has joined Trethera’s Scientific Advisory Board. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards […]